Skip to main content

Advertisement

Table 4 Common Grade 3 or 4 Adverse Events

From: DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Docetaxel/Oxaliplatin (n = 44)
Adverse Event Number of Patients Percent
Hematologic   
 Neutropenia 28 63.6
 Febrile Neutropenia 2 4.5
 Thrombocytopenia 1 2.3
 Anaemia 1 2.3
Non Hematologic   
 Fatigue 2 4.5
 Diarrhea 5 11.4
 Nausea 4 9.1
 Peripheral Neuropathy 1 2.3
G-CSF use 2 4.5
  1. G-CSF granulocyte-colony stimulating factor